Results 191 to 200 of about 192,172 (285)

GM-CSF Armed Oncolytic Adenovirus Enhances T-Cell Infiltration and Suppresses Local and Distal Tumor Growth. [PDF]

Viruses
Xu HW, Wang QW, Zhao M, Jun J, Shu RG, Shi YS, Peng XL, Yu JM, Zheng YP, Fu YH, He JS.   +10 more
europepmc   +1 more source

RORγt‐APCs: The New Masters of Oral Tolerance

Barrier Immunity, EarlyView.
ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley   +1 more source

Adjunctive GM-CSF therapy enhances host defense against systemic <i>Candida auris</i> infection in immunosuppressed mice. [PDF]

Front Immunol
Mattos EC, Das Gupta K, Quintanilla D, Hautau H, Ibrahim AS, Singh S.   +5 more
europepmc   +1 more source

Fibroblast Plasticity in Inflammation of the Barrier

Barrier Immunity, EarlyView.
Under inflammatory condition, fibroblasts in barrier tissues integrate inflammatory, senescent, and mechanical inputs. These pathways activate central signaling networks to drive fibroblast phenotypic transition, enabling cytokine production, immune cell recruitment, and extracellular matrix remodeling.
Chen Zhang, Hao Wu, Wei Li
wiley   +1 more source

The power of GM-CSF: immune regulation in the defense against <i>Phialophora verrucosa</i> infection. [PDF]

Front Immunol
Dong Q, Lu J, Liu M, Wu W, Kang Y, Zhang R.   +5 more
europepmc   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

mGem: When immunity turns against itself-GM-CSF autoantibodies drive opportunistic infection risk. [PDF]

mBio
Sengupta S, Williamson PR.
europepmc   +1 more source

Inhaled GM-CSF for Pulmonary Alveolar Proteinosis

New England Journal of Medicine, 2020
Papiris, S.A., Griese, M., Manali, E.D.
openaire   +3 more sources

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Efficacy and safety of entecavir, peginterferon alfa-2b and GM-CSF combination therapy: the anchor randomized controlled trial. [PDF]

Hepatol Int
Wu D, Huang D, Peng S, Chen Y, Yang F, Zhang X, Fu L, Xu L, Jiang J, Zheng Q, Chen X, Liu Y, Dou X, Ma K, Xi D, Wang P, Sun L, He R, Tian Y, Yin P, Yan W, Han M, Ning Q.   +22 more
europepmc   +1 more source